Locoregional treatment outcomes after multimodality management of inflammatory breast cancer
about
Inflammatory breast cancer: New factors contribute to disease etiology: A reviewInflammatory breast cancer: what we know and what we need to learnCathepsin B: a potential prognostic marker for inflammatory breast cancerSynergy of nab-paclitaxel and bevacizumab in eradicating large orthotopic breast tumors and preexisting metastases.Primary tumor resection as a component of multimodality treatment may improve local control and survival in patients with stage IV inflammatory breast cancerInternational expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatmentTriple-negative subtype predicts poor overall survival and high locoregional relapse in inflammatory breast cancerSocioeconomic and racial disparities in the selection of chest wall boost radiation therapy in californian women after mastectomy.Nanoshell-mediated photothermal therapy can enhance chemotherapy in inflammatory breast cancer cellsRadiation dose escalation for loco-regional recurrence of breast cancer after mastectomy.In Vitro Assessment of the Inflammatory Breast Cancer Cell Line SUM 149: Discovery of 2 Single Nucleotide Polymorphisms in the RNase L Gene.Inflammatory breast cancer: what are the treatment options?Predictors of durable no evidence of disease status in de novo metastatic inflammatory breast cancer patients treated with neoadjuvant chemotherapy and post-mastectomy radiation.Inflammatory breast cancer: the disease, the biology, the treatment.Overview of preoperative radiochemotherapy in breast cancer: past or future?Determinants of optimal mastectomy skin flap thickness.The Impact of Residual Disease After Preoperative Systemic Therapy on Clinical Outcomes in Patients with Inflammatory Breast Cancer.Lymph node status in inflammatory breast cancer.Postmastectomy radiation therapy for inflammatory breast cancer: is more better?Outcomes of patients with inflammatory breast cancer treated by breast-conserving surgery.How do I treat inflammatory breast cancer?Suppression of the xCT-CD44v antiporter system sensitizes triple-negative breast cancer cells to doxorubicin.A Phase 2 Study of Preoperative Capecitabine and Concomitant Radiation in Women With Advanced Breast Cancer.International Consensus on the Clinical Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference.Inflammatory Breast Cancer: Patterns of Failure and the Case for Aggressive Locoregional Management.Influence of patient, physician, and hospital characteristics on the receipt of guideline-concordant care for inflammatory breast cancer.The Impact of Locoregional Therapy in Nonmetastatic Inflammatory Breast Cancer: A Population-Based Study.
P2860
Q27027856-947F87F2-55EB-44CD-A868-058583F6984AQ27028128-C06A8033-D0A5-400E-A2A5-E85AC5AC9D94Q34499322-D6A938C8-C07E-4307-BDBB-AC081E1E3673Q34763649-E2B8B234-45CC-4EE3-A5D0-F112F7F8DF5AQ34782298-D6DC8871-89D4-43D4-9B23-53D5A13DF698Q35017523-DB289785-D1D9-4CA1-A06D-02B66223D4DCQ35642344-4E259F5E-55C0-4936-BFE2-9EE1B081F9E8Q35794994-32455C2C-2053-4BFA-8D81-A25A001A240CQ36277938-120DF4AE-23C4-4F7F-A16B-27E459FF65A6Q36555919-E7FBBF29-05C0-44F4-98B7-842E52E5AA23Q36583979-A5D227F8-B365-407E-AA21-D99D98047FC2Q37642758-9147A148-DDE5-4E65-B249-7CFDDF48BFCFQ37687112-CB6995F0-F88A-4093-93A2-E3000A441D25Q37801500-1B6B6571-1E65-4282-A8A9-292C6B87C2F7Q37903139-4974B649-B82D-449E-BB4A-7986C03892E6Q38199008-E6F1406C-127C-45D7-BDF6-8F5D6E82BAB2Q39339815-D7E0F382-9AC8-44E5-9496-1099551D5B92Q41110592-C0BF5E73-E815-4F85-968E-C64F8E5865F2Q42565561-E988A412-1B4D-4F92-B9F3-29EC8606A93BQ44158111-DC30E08D-2003-488B-A73E-BC7B7FE118D8Q44586994-C2B472AB-8AC3-4891-AC7F-A83143B9E423Q46857381-6D3A300E-DD26-48EC-B2AD-2A77B5D06971Q51800605-741A8F0A-3538-4B92-A319-1938CBB5C3AFQ52714397-66C4FAF3-3501-43B5-96CA-9F698810D513Q54283392-235C774F-F8A7-4F61-90B3-C3DE2936C810Q55122090-C09C6AE0-B57B-470D-99BB-B8A39C43C956Q55405935-4BC9D680-2F77-4F87-AE18-A354E4BBD787
P2860
Locoregional treatment outcomes after multimodality management of inflammatory breast cancer
description
2008 nî lūn-bûn
@nan
2008 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Locoregional treatment outcome ...... of inflammatory breast cancer
@ast
Locoregional treatment outcome ...... of inflammatory breast cancer
@en
Locoregional treatment outcome ...... of inflammatory breast cancer
@nl
type
label
Locoregional treatment outcome ...... of inflammatory breast cancer
@ast
Locoregional treatment outcome ...... of inflammatory breast cancer
@en
Locoregional treatment outcome ...... of inflammatory breast cancer
@nl
prefLabel
Locoregional treatment outcome ...... of inflammatory breast cancer
@ast
Locoregional treatment outcome ...... of inflammatory breast cancer
@en
Locoregional treatment outcome ...... of inflammatory breast cancer
@nl
P2093
P2860
P1476
Locoregional treatment outcome ...... of inflammatory breast cancer
@en
P2093
Aysegul A Sahin
Delora Domain
Eric A Strom
Gabriel N Hortobagyi
George H Perkins
Ian J Bristol
Julia L Oh
Kelly K Hunt
Massimo Cristofanilli
S Eva Singletary
P2860
P304
P356
10.1016/J.IJROBP.2008.01.039
P407
P577
2008-04-24T00:00:00Z